Navigation Links
Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions

AURORA, Ontario, Oct. 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47.   These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.  

The Company plans to conduct a Phase I study in the U.S. in patients with refractory solid tumors and a  Phase I/II, multi-arm safety and preliminary efficacy study in patients with stage III/IV non-small cell lung cancer in Poland.  It intends to use the findings from its GLP toxicology studies to complete the necessary protocol designs and other supportive documentation, as final steps in preparing its U.S. Phase I IND and its Polish Phase I/II CTA dossiers.  As a result of some delays in completing its GLP toxicology studies, Helix now expects these IND/CTA submissions to be made in its second rather than its first quarter of fiscal 2011.  

"We are very pleased to reach this important clinic-enabling milestone in our L-DOS47 development program," said John Docherty, Helix president and COO.  "Having completed these studies, Helix believes it now has a sufficient preclinical pharmacology and toxicology database to support human clinical testing with this important new drug candidate.  Helix is committed to completing these submissions as soon as possible, as it is no longer waiting for any further preclinical study findings before doing so."

About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies.  Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidates. Helix is listed on the Toronto, NYSE Amex and Frankfurt Stock Exchanges under the symbol "HBP".  For more information, please visit For further information contact:Robert Flamm, Ph.D.Russo Partners, LLCTel: (212) 845-4226Email:   This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements") regarding the intended use by Helix BioPharma Corp. ("Helix" or the "Company") of GLP toxicology study findings for L-DOS47 and its belief regarding their support for human clinical testing, its plans to conduct clinical trials of L-DOS47, its expected timing of L-DOS47 IND/CTA submissions, and its drug product development, which statements and information can be identified by the use of forward looking terminology such as "plans", "intends", "expects", "believes",  "committed to" and "developing".  Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements.  Certain material factors or assumptions applied in making forward-looking statements include without limitation, that Helix's toxicology studies will support human testing, Helix's receipt of regulatory approvals and necessary funding, the expeditious completion of its IND and CTA dossiers, and the safety and efficacy of Helix's drug candidates.  Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all; uncertainty whether the Company's drug candidates will be successfully developed and commercialized; the need for further regulatory approvals, which are not assured; the Company's dependence on performance by third parties; uncertainty whether the Company's planned clinical trials referred to in this news release will be approved, conducted or achieve expected results; product liability and insurance risks; uncertainties related to research and development, including manufacturing risks; intellectual property risks; and the risk of changes in business strategy or development plans. Investors should consult the Company's quarterly and annual filings, including its latest Form 20-F, with the Canadian and U.S. securities commissions at and at for additional information on these and other risks and uncertainties which may affect the Company. Investors are cautioned against placing undue reliance on forward-looking statements. Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, assumptions, opinions or expectations change, except as required by law. 


SOURCE Helix BioPharma Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix Biopharma Closes $11.4 Million Private Placement
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
6. Helix BioPharma Announces Q1 2009 Financial Results
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
10. Helix BioPharma Announces Q2 2009 Financial Results
11. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/18/2015)... 2015 --> ... market report titled  Gesture Recognition Market - Global Industry ... 2021. According to the report, the global gesture recognition market was valued ... reach US$29.1 bn by 2021, at a CAGR of ... America dominated the global gesture recognition market ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):